Puma Biotechnology
PBYI
203 hedge funds and large institutions have $3.58B invested in Puma Biotechnology in 2017 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 76 increasing their positions, 56 reducing their positions, and 20 closing their positions.
165% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 20
36% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 56
19% more funds holding
Funds holding: 171 → 203 (+32)
7% less call options, than puts
Call options by funds: $72.5M | Put options by funds: $77.8M
2.13% less ownership
Funds ownership: 98.59% → 96.46% (-2.1%)
19% less capital invested
Capital invested by funds: $4.39B → $3.58B (-$814M)
50% less funds holding in top 10
Funds holding in top 10: 12 → 6 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$276M |
| 2 |
D.E. Shaw & Co
New York
|
+$96M |
| 3 |
BlackRock
New York
|
+$63.8M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$52.2M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$50.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$367M |
| 2 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$73.6M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$65.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$45.4M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$37.6M |
PBYI Hedge Fund Activity: Q4 2017 in Review
203 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q4 2017, worth a combined $3.58B — down 19% from $4.39B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new PBYI positions and 20 closed out — a net gain of 33 holders — while 76 added to existing stakes and 56 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $276M. The largest seller was T. Rowe Price Associates, cutting an estimated $367M.
- 203 institutional investors held Puma Biotechnology (PBYI) as of Q4 2017, up from 171 in Q3 2017.
- Funds reported $3.58B of Puma Biotechnology stock for Q4 2017, down 19% quarter-over-quarter.
- 53 funds opened new Puma Biotechnology positions in Q4 2017 and 20 closed out, a net change of +33 holders.
- The largest Puma Biotechnology buyer in Q4 2017 was Janus Henderson Group, an estimated $276M added.
- The largest Puma Biotechnology seller in Q4 2017 was T. Rowe Price Associates, an estimated $367M sold.
Based on aggregated 13F filings for Q4 2017.